IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
NASDAQ:IDXX - Nasdaq - US45168D1046 - Common Stock
IDXX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. IDXX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IDXX is not valued too expensively and it also shows a decent growth rate. These ratings would make IDXX suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year IDXX was profitable.
In the past year IDXX had a positive cash flow from operations.
In the past 5 years IDXX has always been profitable.
IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IDXX (25.85%) is better than 98.95% of its industry peers.
With an excellent Return On Equity value of 53.54%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 34.02%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.08%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.85% | ||
| ROE | 53.54% | ||
| ROIC | 34.02% |
ROA(3y)27.07%
ROA(5y)25.98%
ROE(3y)92.14%
ROE(5y)121.89%
ROIC(3y)36.89%
ROIC(5y)34.87%
1.3 Margins
With an excellent Profit Margin value of 22.53%, IDXX belongs to the best of the industry, outperforming 94.21% of the companies in the same industry.
IDXX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 28.92%, IDXX belongs to the top of the industry, outperforming 96.84% of the companies in the same industry.
IDXX's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 60.72%, IDXX is doing good in the industry, outperforming 61.05% of the companies in the same industry.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.92% | ||
| PM (TTM) | 22.53% | ||
| GM | 60.72% |
OM growth 3Y5.32%
OM growth 5Y5.96%
PM growth 3Y2.4%
PM growth 5Y6.27%
GM growth 3Y1.01%
GM growth 5Y1.29%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
IDXX has about the same amout of shares outstanding than it did 1 year ago.
IDXX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 16.65 indicates that IDXX is not in any danger for bankruptcy at the moment.
IDXX's Altman-Z score of 16.65 is amongst the best of the industry. IDXX outperforms 92.63% of its industry peers.
IDXX has a debt to FCF ratio of 1.10. This is a very positive value and a sign of high solvency as it would only need 1.10 years to pay back of all of its debts.
IDXX has a better Debt to FCF ratio (1.10) than 90.53% of its industry peers.
IDXX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
IDXX's Debt to Equity ratio of 0.48 is on the low side compared to the rest of the industry. IDXX is outperformed by 60.53% of its industry peers.
Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 1.1 | ||
| Altman-Z | 16.65 |
ROIC/WACC3.76
WACC9.05%
2.3 Liquidity
A Current Ratio of 1.42 indicates that IDXX should not have too much problems paying its short term obligations.
IDXX's Current ratio of 1.42 is on the low side compared to the rest of the industry. IDXX is outperformed by 77.89% of its industry peers.
IDXX has a Quick Ratio of 1.03. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
IDXX's Quick ratio of 1.03 is on the low side compared to the rest of the industry. IDXX is outperformed by 74.21% of its industry peers.
IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.73% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.72% yearly.
The Revenue has been growing slightly by 7.16% in the past year.
IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.59% yearly.
EPS 1Y (TTM)11.73%
EPS 3Y14.49%
EPS 5Y18.72%
EPS Q2Q%10.67%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y10.59%
Revenue growth 5Y10.59%
Sales Q2Q%6.56%
3.2 Future
The Earnings Per Share is expected to grow by 10.80% on average over the next years. This is quite good.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.13% yearly.
EPS Next Y6.88%
EPS Next 2Y10.17%
EPS Next 3Y11.14%
EPS Next 5Y10.8%
Revenue Next Year6.34%
Revenue Next 2Y6.76%
Revenue Next 3Y7.33%
Revenue Next 5Y8.13%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 39.03, which means the current valuation is very expensive for IDXX.
Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 71.58% of the companies listed in the same industry.
IDXX's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 28.29.
A Price/Forward Earnings ratio of 34.96 indicates a quite expensive valuation of IDXX.
Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than the industry average as 73.16% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.44, IDXX is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.03 | ||
| Fwd PE | 34.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than 74.21% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 79.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.15 | ||
| EV/EBITDA | 28.52 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IDXX may justify a higher PE ratio.
PEG (NY)5.68
PEG (5Y)2.08
EPS Next 2Y10.17%
EPS Next 3Y11.14%
5. Dividend
5.1 Amount
No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IDEXX LABORATORIES INC
NASDAQ:IDXX (1/21/2025, 8:06:56 PM)
After market: 427.33 0 (0%)427.33
+8.07 (+1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners96.26%
Inst Owner Change0.14%
Ins Owners0.22%
Ins Owner Change-51.34%
Market Cap34.99B
Analysts77.14
Price Target499.57 (16.9%)
Short Float %1.84%
Short Ratio2.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.67%
Min EPS beat(2)2.49%
Max EPS beat(2)2.84%
EPS beat(4)4
Avg EPS beat(4)3.94%
Min EPS beat(4)2.49%
Max EPS beat(4)7.31%
EPS beat(8)8
Avg EPS beat(8)4.15%
EPS beat(12)10
Avg EPS beat(12)3.48%
EPS beat(16)14
Avg EPS beat(16)8.43%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-2.33%
Max Revenue beat(2)-2.19%
Revenue beat(4)0
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-2.33%
Max Revenue beat(4)-0.82%
Revenue beat(8)0
Avg Revenue beat(8)-1.72%
Revenue beat(12)1
Avg Revenue beat(12)-1.55%
Revenue beat(16)4
Avg Revenue beat(16)-0.56%
PT rev (1m)0.84%
PT rev (3m)-7.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.32%
EPS NY rev (1m)0%
EPS NY rev (3m)0.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.03 | ||
| Fwd PE | 34.96 | ||
| P/S | 9.1 | ||
| P/FCF | 44.15 | ||
| P/OCF | 38.17 | ||
| P/B | 21.62 | ||
| P/tB | 31.83 | ||
| EV/EBITDA | 28.52 |
EPS(TTM)10.95
EY2.56%
EPS(NY)12.22
Fwd EY2.86%
FCF(TTM)9.68
FCFY2.27%
OCF(TTM)11.2
OCFY2.62%
SpS46.96
BVpS19.76
TBVpS13.42
PEG (NY)5.68
PEG (5Y)2.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.85% | ||
| ROE | 53.54% | ||
| ROCE | 47.49% | ||
| ROIC | 34.02% | ||
| ROICexc | 38.62% | ||
| ROICexgc | 49.99% | ||
| OM | 28.92% | ||
| PM (TTM) | 22.53% | ||
| GM | 60.72% | ||
| FCFM | 20.61% |
ROA(3y)27.07%
ROA(5y)25.98%
ROE(3y)92.14%
ROE(5y)121.89%
ROIC(3y)36.89%
ROIC(5y)34.87%
ROICexc(3y)41.26%
ROICexc(5y)39.79%
ROICexgc(3y)54.84%
ROICexgc(5y)52.3%
ROCE(3y)54.37%
ROCE(5y)50.75%
ROICexcg growth 3Y-0.47%
ROICexcg growth 5Y0.97%
ROICexc growth 3Y-0.1%
ROICexc growth 5Y1.82%
OM growth 3Y5.32%
OM growth 5Y5.96%
PM growth 3Y2.4%
PM growth 5Y6.27%
GM growth 3Y1.01%
GM growth 5Y1.29%
F-Score6
Asset Turnover1.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 1.1 | ||
| Debt/EBITDA | 0.63 | ||
| Cap/Depr | 98.62% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.06% | ||
| Profit Quality | 91.5% | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 16.65 |
F-Score6
WACC9.05%
ROIC/WACC3.76
Cap/Depr(3y)124.15%
Cap/Depr(5y)132.24%
Cap/Sales(3y)4.03%
Cap/Sales(5y)4.5%
Profit Quality(3y)77.81%
Profit Quality(5y)79.47%
High Growth Momentum
Growth
EPS 1Y (TTM)11.73%
EPS 3Y14.49%
EPS 5Y18.72%
EPS Q2Q%10.67%
EPS Next Y6.88%
EPS Next 2Y10.17%
EPS Next 3Y11.14%
EPS Next 5Y10.8%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y10.59%
Revenue growth 5Y10.59%
Sales Q2Q%6.56%
Revenue Next Year6.34%
Revenue Next 2Y6.76%
Revenue Next 3Y7.33%
Revenue Next 5Y8.13%
EBIT growth 1Y3.12%
EBIT growth 3Y16.47%
EBIT growth 5Y17.18%
EBIT Next Year18.59%
EBIT Next 3Y12.46%
EBIT Next 5Y10.28%
FCF growth 1Y80.87%
FCF growth 3Y12.68%
FCF growth 5Y22.76%
OCF growth 1Y58.2%
OCF growth 3Y11.83%
OCF growth 5Y17.77%